| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* General Hospital St. Georg, Department of Hematology, Hamburg, Germany;
Institute of Immunology, University of Kiel, Kiel, Germany;
Department of Stem Cell Transplantation, University of Heidelberg, Heidelberg, Germany; and
Department of Microbiology and Immunology, University of South Alabama College of Medicine, Mobile, AL 36602
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
In the present study, we identified and characterized two distinct HLA-A*0201-specific OFA-iLR peptide-epitopes using Ag-specific CTLs that were generated by in vitro priming with peptides-pulsed monocyte-derived DCs. We demonstrate that OFA-iLRP peptide-specific CTLs obtained from healthy donors and patients with acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) elicited Ag-specific HLA-A*0201-restricted cytolytic activity against several hematological tumor cell lines and freshly isolated AML and CLL tumor cells. Furthermore, by detecting OFA-iLR-specific T lymphocytes in patients with CLL and multiple myeloma (MM) in an early stage of disease but not in patients with progressive disease, OFA-iLR-specific CTLs can play a role in controlling OFA-iLR+ tumor cells.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
PBMCs and bone marrow (BM) cells from healthy donors and malignant cells from patient with AML, CLL, and MM were obtained by Ficoll density gradient centrifugation after informed consent and approval by our institutional review board. Patient characteristics are reported in Tables I and II. PBMCs obtained from healthy individuals and patients were stained with the anti-HLA-A*0201-FITC mAb (Biologo) and analyzed by flow cytometry and CellQuest software (FACScan; BD Biosciences). HLA-A2-positivity was confirmed by genotyping of the HLA-A2*0201 allele.
|
|
K562 (erythroleukemia), U-266 and IM-9 (plasmacytoma), Karpas-422, Balm-3, REH, Ramos (B lymphoblastic lymphoma), and T2 cells were obtained from American Type Culture Collection. MEC-1 (chronic lymphocytic leukemia) was a gift from Dr. F. Caligaris-Cappio (University of Torino, Torino, Italy). CD34+ peripheral blood progenitor cells were obtained using MACS technology (Miltenyi Biotec), following the manufacturer’s instructions. The cell purity was verified by FACS analysis (FACScan; BD Biosciences) and reached > 90%.
Peptides and loading of T2 cells
For binding assay and generation of peptide-specific CTLs, the peptide from influenza A virus matrix protein M1, FluM158–66 (GILGFVFTL, positive control), HIV-Pol476–484 (ILKEPVHGV, positive control), msurv33 (LYLKNYRIA, murine survivin peptide epitope specific for H-2d, negative control), iLR159–68 (LLAARAIVAI, Rammensee score: 18), iLR2146–154 (ALCNTDSPL, Rammensee score: 22), iLR360–68 (LAARAIVAI, Rammensee score: 23), iLR458–66 (LLLAARAIV, Rammensee score: 26), iLR57–15 (VLQMKEEDV, Rammensee score: 22), iLR650–58 (NLKRTWEKL, Rammensee score: 21), iLR766–74 (VAIENPADV, Rammensee score: 21), iLR8139–147 (YVNLPTIAL, Rammensee score: 21), iLR9177–185 (MLAREVLRM, Rammensee score: 21), iLR10249–257 (SEGVQVPSV, Rammensee score: 19), iLR1118–26 (FLAAGTHLG, Rammensee score: 18), iLR1257–66 (KLLLAARAIV, Rammensee score: 25), iLR1367–76 (AIENPADVSV, Rammensee score: 23), and iLR14173–182 (LMWWMLAREV, Rammensee score: 23) were selected by prediction to bind to the HLA-A*0201 molecule using the computer programs PAProC (
www.uni-tübingen.de/uni/kxi
) and SYFPEITHI (www.syfpeithi.de). The peptides, which were purchased from Biosynthan, were provided with >90% purity and were analyzed by HPLC and mass spectometry. The HLA-A2-positive mutant cell line T2 was incubated with peptides for 2 h at 37°C and 5% CO2 at various concentrations, washed three times with PBS (Biochrom), and used as targets in 51Cr release or T2-binding assays.
MHC-binding and stabilization assay
Evaluation of HLA-A2-binding affinity was performed by flow cytometry analysis based on the use of the HLA-A*0201 TAP-deficient T2 lymphoma cell line using a modified protocol adopted from Casati et al. (9). T2 cells (2.5 x 106/ml) were seeded in RPMI 1640 (Invitrogen Life Technologies) with 2.5 µg/ml 
2-microglobulin (Sigma-Aldrich). Peptides were added at various concentrations. Cells were incubated overnight in a water-saturated atmosphere with 5% CO2 at 37°C. After incubation, cells were washed with cold PBS with 0.05% BSA (Sigma-Aldrich) to remove unbound peptides. To determine surface expression of the HLA-A2 molecule, cells were resuspended in 100 µl of PBS/0.05% BSA and incubated with 10 µl of anti-HLA-A*0201-FITC mAb for 30 min at 4°C. Afterward, cells were washed twice with cold PBS/0.05% BSA. Fluorescence intensity was measured by FACS analysis. Controls consisted of T2 cells cultured with FluM1 (positive control), msurv33, or with no peptide (negative controls).
To determine the stability of the peptide/HLA-A2 complex, 2 x 106 T2 cells were incubated overnight at 27°C in 2 ml of RPMI 1640 supplemented with 10% FCS and 2.5 µg/ml 2-microglobulin. Peptides were added at a concentration of 10 µM. Cells were then washed and incubated at 37°C for 0, 2, 4, 6, or 8 h. HLA-A2 expression on these cells was determined, as described above. Results are expressed as percentage (over control) of the remaining BB7.2 mean fluorescence intensity. Controls are the BB7.2 mean fluorescence intensity of T2 cells at the onset of incubation at 37°C.
Western blot analysis
Whole cell protein extracts were prepared from 1 x 107 cells using a lysis buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Nonidet P-40 (Sigma-Aldrich), 2 mM EDTA (pH 8.0), and Complete mini (protease inhibitor; Roche). Cell lysates were separated by 12% gels in SDS-PAGE under reducing conditions for 60 min at 140 V. Proteins were transferred onto a nitrocellulose membrane (Macherey & Nagel) in 25 mM Tris base, 0.2 M glycine, and 20% methanol for 60 min at 100 V and blocked in 20 mM Tris (pH 8.0), 137 mM NaCl, and 0.1% Tween 20 (TBST), and 5% powdered milk overnight. Immunoblottings were performed using the mouse anti-OFA-iLRP mAb at a concentration of 0.75 µg/ml (in TBST and 5% BSA) as primary and horseradish phosphatase-linked goat anti-mouse IgG (Dianova) (diluted to 1/5000 v/v in TBST and powdered milk) as secondary Ab. All immunoblots were performed using Enhanced Chemoluminescence solution (ECL; Amersham Biosciences), following the manufacturer’s instructions.
ELISPOT assay
PBMCs (106/ml) obtained after Ficoll density gradient centrifugation from HLA-A*0201 patients with AML, CLL, and MM were cultured in AIMV medium (Invitrogen Life Technologies) with 5% heat-inactivated human AB serum (CC-Pro) and 10 µg of peptide for 10 days. After 24 h, IL-2 (CellConcepts) was added at a concentration of 20 IU/ml. Nitrocellulose plates (96-well; MAHA S4510; Millipore) were coated overnight with 100 µl/well of 10 µg/ml anti-human IFN-
mAb (Mabtech) in PBS by 4°C. Afterward, plates were washed three times with 150 µl/well PBS for 5 min and blocked with AIMV medium for 1 h in 5% CO2 at 37°C. After blocking, 1 x 105 precultured cells in a volume of 50 µl/well were seeded, and peptides at a concentration of 10 µg/ml in 50 µl of AIMV medium were added to cells. Plates were incubated for 18–20 h by 37°C with 5% CO2. Plates were then washed six times for 3 min with TBS (Bio-Rad) and 0.05% Tween 20 (Sigma-Aldrich), and wells were incubated with 100 µl/well of biotinylated mouse anti-human IFN- mAb (Mabtech) at a concentration of 2 µg/ml in TBS for 2 h by 37°C and 5% CO2. After washing six times, ExtrAvidin alkaline phosphatase conjugate (1 µg/ml in TBS; Sigma-Aldrich) was added for 1 h at room temperature. Next, plates were washed three times with TBS/0.05% Tween20 and five times with TBS only. Development of the spots was performed by adding 100 µl/well of 5-bromo-4-chloro-3-indolyl phosphate/NBT substrate for 10–30 min in darkness. IFN--secreting T cells were counted using the automated image analysis system ELISPOT Reader (AID). Each experiment was performed in duplicate.
Pentamer staining
To determine the frequency of OFA-iLR-specific CD8+ T cells in HLA-A2+individuals, FluM158–66-pentamer-PE (positive control), HIV-Pol476–484-pentamer-PE (negative control), iLR159–68-pentamer-PE, and iLR2146–154-pentamer-PE were used (Proimmune). Peptide-prestimulated PBMCs (see ELISPOT assay) were incubated with 10 µl of pentamer for 30 min in darkness. Cells were washed and resuspended in 100 µl of wash buffer. PBMCs were incubated with FITC-conjugated anti-CD8 mAb (Caltag Laboratories) for 25 min by 4°C and washed twice with wash buffer. To exclude dead cells, propidium iodide (Sigma-Aldrich) was added at a concentration of 1 µg/ml. Fluorescence intensity was determined by FACS analysis. The percentage of peptide-specific T cells was determined after gating the CD8+ T cells inside the T cell population. Analysis was performed using the CellQuest Pro software.
Generation of mature DCs and loading with peptides
Mature DCs from healthy HLA-A*0201 donors were generated following the protocol of Feuerstein et al. (10). A concentrated leukocyte fraction was generated through a 2-h restricted peripheral blood leukapheresis processing 6–8 liters of blood with each collection. A total of 2 x 108 PBMCs/ml obtained after Ficoll density gradient centrifugation was incubated in 30 ml of serum-free AIMV medium (Invitrogen Life Technologies) for 2 h in a water-saturated atmosphere with 5% CO2 at 37°C. The nonadherent T cell-enriched fraction was cryoconserved and used later as a source of CTL generation. The adherent monocytes were cultured for 5 days with 500 U/ml human IL-4 and 800 U/ml human GM-CSF (CellConcepts) to obtain immature DCs (iDCs). Maturation of DCs was performed in AIMV medium (Invitrogen Life Technologies) by adding human IL-1, human TNF-
(10 ng/ml; CellConcepts), human IL-6 (1000 U/ml; CellConcepts), and human PGE2 (1 µg/ml; Sigma-Aldrich) for 2 additional days at 37°C with 5% CO2.
Mature DCs from patients with AML and CLL were generated by separating PBMCs from 100 ml of whole blood donation, following the protocol described above. Loading of the mature DCs with peptide was performed by incubation of 1 x 106/ml mature DCs with 50 µg/ml peptide for 2 h at 37°C with 5% CO2.
Isolation of human OFA-iLRP coding RNA and EGFP-RNA
Preparation of an OFA-iLRP expression vector was done as described previously (6). The vector was transformed into Escherichia coli JM83 by heat shock transformation. After ampicillin selection, plasmid isolation (Plasmid Maxi kit; Qiagen) was performed, and the correct size of the plasmid was checked on a 1% agarose gel. OFA-iLRP sequence was verified by automatic sequencing (ABI 310; PerkinElmer). Resulting plasmid DNA was linearized, and in vitro transcription was performed using the T7 RiboMAX Large Scale Transcription kit (Promega) as described previously (6). EGFP vector was provided by Dr. M. Marget (Institute of Immunology, University of Kiel, Kiel, Germany). Quantity and purity of the RNA was determined by UV spectrophotometry.
OFA-iLR-RNA transfection and maturation of human DCs
Transfection of iDCs with in vitro-transcribed iLRP-RNA was performed by using the liposomal transfection reagent dioleoyloxy-trimethylammonium-propane-methylsulfate (DOTAP; Roche). DOTAP (20 µl) and in vitro-transcribed RNA (10 µg) were mixed in 500 µl of Opti-MEM (Invitrogen Life Technologies) and incubated for 20 min at room temperature. The RNA-lipid complex was added to 1 x 106 iDCs/ml (in Opti-MEM) and incubated at 37°C for 3 h. Maturation of the transfected iDCs was performed by culturing for 2 days in serum-free medium supplemented with GM-CSF, IL-4, IL-1, TNF- (10 ng/ml; CellConcepts), IL-6 (1000 U/ml; CellConcepts), and PGE2 (1 µg/ml; Sigma-Aldrich). Flow cytometric analysis revealed that 
30% of iLRP-RNA-transfected and maturated DCs expressed iLRP and high levels of CD80, CD83, CD86, MHC class I, and MHC class II molecules.
Generation of CTLs
CTLs were generated, as described previously (11). A total of 2 x 107 cryoconserved nonadherent PBMCs was cultured with 2 x 106/ml autologous OFA-iLR peptide-pulsed DCs in 10 ml of AIMV medium (Invitrogen Life Technologies) supplemented with 20 U/ml human IL-2 and 10 ng/ml human IL-7 (CellConcepts). Cells were weekly restimulated with peptide-loaded DCs.
For the induction of autologous peptide-specific CTLs obtained from patients with AML and CLL, CD8+ T cells were separated from PBMCs using immunomagnetic beads (MACS beads; Miltenyi Biotec), following the manufacturer’s instructions. Cells were cultured with autologous OFA-iLR peptide-pulsed DCs and weekly restimulated with autologous peptide-pulsed PBMCs in the presence of IL-2 (1 ng/ml; CellConcepts). After three to four restimulations, >90% of cells in each culture were CD3+ lymphocytes, of which >90% were CD8+ and 3.5–4.8% were CD4+. Cultures contained <1.5% CD14+ and 3.5–4.5% CD56+ cells. In another set of experiments, peptide-specific CTLs were enriched from CLL patients using the IFN- secretion assay (Miltenyi Biotec), as described previously (6). CTL reactivity was determined in a conventional 4-h 51Cr release assay.
51Cr release assay, cold target inhibition assay, and Ab-blocking experiments
Standard 4-h 51Cr release assay was performed, as described previously (11). Specificity of tumor cell lysis was determined in a cold target inhibition assay by analyzing the capacity of unlabeled HLA-A2+ iLRP-negative T2 cells, OFA-iLR peptide (iLR1 + iLR2)- and msurv33 peptide-labeled T2 cells, and OFA-iLR-positive leukemic blasts from an HLA-A*0201 AML patient (AML-01) to block lysis of tumor cells at a ratio of 20:1 (inhibitor:target ratio).
For Ab-blocking experiments, human CTLs were generated as described above. Tumor cells were incubated with 10 µg/ml anti-HLA-A2 mAb (BB7.2; BD Biosciences), and CTLs were incubated with anti-CD8 (T8), anti-Pan-TCR (BMA 031), and anti-CD4 (T4) isotype-matched controls MAM-6 and HMFG-1 (Beckman Coulter) for 30 min. Cell suspensions were washed twice with complete medium and tested in a 51Cr release assay.
Statistics
Student’s t test was performed to evaluate the significance of the results.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
The expression of OFA-iLRP in or on malignant and nonmalignant cells was assessed by Western blot and FACS analyses using the previously described anti-OFA-iLRP mAb. All hematological tumor samples used in this study showed a strong up-regulation of OFA-iLRP expression. In Fig. 1, some representative samples are demonstrated. As expected, we could not detect any OFA-iLRP expression in nonmalignant hemopoietic cell subtypes (CD34+ progenitor cells, bone marrow cells, B cells, and activated B cells).
|
To identify T cell-binding epitopes deduced from the OFA-iLR protein, 14 peptides were synthesized that were predicted by the computer programs PAProC (www.uni-tuebingen.de/uni/kxi/[Lang]) and SYFPEITHI (www.syfpeithi.de) to bind to the HLA-A*0201 molecule (see Materials and Methods). In an in vitro reconstitution assay using the TAP-deficient T2 cell line, two peptides (iLR1 and iLR2) showed similar binding affinity to HLA-A*0201 (Fig. 2A) as the positive control Flum1. In addition, as illustrated in Fig. 2C, the HLA-A2/iLR1 and HLA-A2/iLR2 complexes showed intermediate complex stability when compared with the Flum1 peptide.
|
Detection of OFA-iLR peptide-specific T cells in patients with hemopoietic malignancies
In a next set of experiments, iLR1 and iLR2 peptides were tested for their potential to elicit specific ex vivo T cell responses in healthy volunteers and in patients with CLL, AML, and MM. To extend the sensitivity of the ELISPOT assay, PBMCs were stimulated with OFA-iLR peptides once in vitro before analysis. As depicted in Fig. 3, in 9 of 21 (43%) and 10 of 21 (48%) of CLL patients, significant frequencies of iLR1 (Fig. 3A)- and iLR2 (Fig. 3B)-specific T cell responses were detected, whereas no spontaneous T cell responses against both peptide epitopes occurred in peripheral blood samples of 15 HLA-A2*0201-positive healthy individuals. In patients with AML, 6 of 15 (40%) mounted a CTL response against iLR1 or iLR2 peptide, respectively. We also analyzed PBMCs from 12 HLA-A*0201-positive patients with MM and detected in 6 samples (50%) a reactivity against iLR1 and iLR2. Additionally, in PBMCs of several leukemia and myeloma patients tested, we also found spontaneous T cell reactivity against the peptides iLR3, iLR4, iLR9, and iLR14 (Fig. 3, C–F). Interestingly, significant frequencies of OFA-iLR peptide-specific CTLs were only found in blood samples of CLL and MM patients in an early stage of disease. In 8 of 14 patients with a Binet A CLL, iLR1- and iLR2-specific T cell reactivity was detected, whereas in CLL patients with progressive disease (Binet C), no OFA-iLR-specific T cell responses occurred (Table I). Similar results were obtained in MM patients.
|
secretion assay. The majority of the iLR1- and iLR2-specific T lymphocytes was CCR7–CD45RA+ memory effector cells (data not shown).
|
In five CLL patients with significant OFA-iLR responses in the ELISPOT assay, we also determined the frequency of iLR1- and iLR2-specific CD8+ T lymphocytes within the PBMCs by performing pentamer staining. Two-color flow cytometry with anti-CD8 mAb and HLA-A2/iLR1- and HLA-A2/iLR2-pentameric complexes revealed a frequency of CD8+ T cells recognizing the iLR1 and iLR2 peptides, respectively, ranging from 0.6 to 2.5% for iLR1 peptide and 0.5 to 1.5 for iLR2 peptide. In contrast, in the presence of the HIV peptide (negative control) or the Flum1 (positive control), we detected frequencies between 0.01 to 0.04% and 5.4 to 23.3%, respectively (one representative experiment shown in Fig. 5).
|
We next analyzed the ability of the in vitro-induced CTLs to lyse tumor cells that express the OFA-iLR protein. Both CTL lines specific for iLR1 (Fig. 6A) or iLR2 (Fig. 6B) elicited strong cytolytic activity against the HLA-A*0201+/OFA-iLR+ hematological tumor lines Karpas-422, Balm-3, IM-9, U266, REH, and Ramos. There was no recognition of the HLA-A2-negative tumor lines MEC-1 and K562. In addition, iLR1- and iLR2-specific T cell lines recognized and efficiently killed HLA-A2+/OFA-iLR+ primary malignant AML blasts (Fig. 7, A and B) and CLL cells (Fig. 7, C and D) but spared HLA-A2-negative targets and normal hemopoietic cells (Fig. 7).
|
|
|
To test the presentation of OFA-iLR-specific T cell epitopes upon transfection with OFA-iLR-coding RNA, we used autologous DCs, generated from the same PBMCs that were used for CTL induction, as target cells. As illustrated in Fig. 5, C and D, ILR1- and iLR2-specific CTLs efficiently lysed autologous DCs transfected with the OFA-iLR-coding RNA, whereas DCs pulsed with the Flum1 peptide or the enhanced EGFP-RNA were not recognized. These findings demonstrate that the identified OFA-iLR peptides iLR1 and iLR2 are processed and presented after transfection of DCs with the OFA-iLR-RNA.
OFA-iLR peptide-specific CTLs lysed autologous malignant hemopoietic cells
In one patient with CLL (Fig. 9, A and B) and in another with AML (Fig. 9, C and D), we were able to generate autologous CTL lines that were specific for the peptides iLR1 and iLR2. These CTLs were capable of efficiently lysing autologous and allogeneic HLA-A2-matched malignant cells endogenously expressing OFA-iLR protein, whereas HLA-A2-negative tumor cells were not recognized and killed. To provide more direct evidences that patient-derived iLR-specific CTLs are functionally active, CD8+ T lymphocytes specifically recognizing the iLR1 and iLR2 epitopes separately were highly enriched from peripheral blood samples obtained from a CLL patient (CLL-02). As depicted in Fig. 9, E and F, both iLR1- and iLR2-specific epitopes CTLs were capable of recognizing autologous tumor cells, whereas allogeneic CLL cells were not attacked.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
In the current study, we screened the OFA-iLR protein for HLA-A2-binding peptides using the computer-assisted software SYFPEITHI. In a standard T2-binding assay, 2 of 14 candidate peptides, iLR1 and iLR2, exhibited a high binding affinity to the HLA-A*0201 molecule. To analyze whether these epitopes are presented by tumor cells endogenously expressing OFA-iLR protein, we generated OFA-iLR peptide-specific CTLs in the presence of monocyte-derived autologous fully matured DCs that had been loaded with iLR1 and iLR2, respectively. After several rounds of restimulations, T cell lines were tested for their cytotoxic capacity against OFA-iLR-expressing hematological tumor lines and primary malignant cells from CLL and AML patients. The in vitro-induced peptide-specific CTLs not only recognized and killed tumor lines but also freshly isolated patient-derived leukemic cells. The specificity of the lytic activity was confirmed by Ab-blocking experiments and cold target inhibition assays.
As shown in Fig. 3, spontaneous T cell responses were also detectable against the OFA-derived peptides iLR3, iLR4, iLR9, and iLR14 having a lower binding affinity to the HLA-A2 molecule than iLR1 or iLR2, as determined in the T2-binding assay. Whereas iLR360–68 (LAARAIVAI), iLR458–66 (LLLAARAIV), and iLR159–68 (LLAARAIVAI) share the identical core amino acid sequence, the peptides iLR9177–185 (MLAREVLRM) and iLR14173–182 (LMWWMLAREV) might represent another potential distinct T cell epitope. Immunological studies are currently underway in our lab to analyze these peptides further.
We further analyzed the specificity of in vitro-generated CTL lines recognizing iLR1 and iLR2 epitopes by using autologous DCs as target cells loaded with the cognate peptides or transfected with the OFA-ILR-coding RNA. ILR1 and iLR2 peptide-specific CTLs were capable of efficiently lysing both peptide-pulsed DCs and DCs transfected with OFA-ILR-RNA. These data clearly demonstrate that the peptides used for CTL induction are endogenously processed and presented by OFA-iLR RNA-transfected DCs. In two patients with hematological malignancies, we were able to generate autologous iLR1 and iLR2 peptide-specific CTLs recognizing and killing autologous OFA-iLR-expressing leukemic cells in an MHC-restricted and Ag-specific manner. These findings, together with the ELISPOT analyses and the pentamer stainings, demonstrate that OFA-iLR-specific CTLs can be detected and generated in patients with hemopoietic malignancies.
The induction of autoimmunity in individuals treated with tumor-associated vaccines represents a potential risk and thus merits careful consideration (16). Our previous studies (6) and the findings described in the present study provide some evidence that the autoimmunogenic potential of OFA-iLR-derived peptides seems to be low. First, by using ELISPOT assay and pentamer staining, we detected OFA-iLR peptide-specific T lymphocytes in a significant proportion of patients without the occurrence of a clinical manifestation of autoimmune diseases; second, iLR1 and iLR2 peptide-specific CTLs did not recognize and lyse normal HLA-A2-matched hemopoietic cell subpopulations, including B cells, activated B cells, DCs, CD34+ progenitor cells, and bone marrow cells; third, OFA-iLR epitopes were not recognized by T lymphocytes from healthy donors; fourth, iLR-specific CTLs obtained from a patient with a clinically overt autoimmune disease (GVHD) displayed no differences in their functional avidity than CTLs from a patient lacking GVHD; and fifth, treatment of mice with syngeneic bone marrow-derived DCs transfected with the murine OFA-iLR-coding RNA resulted in significant antitumor activity against a B cell lymphoma without inducing any macroscopic or histologic signs of autoimmune reactivity (6). We have shown previously that OFA-iLR-specific regulatory CD8+ T cell clones secreting IL-10 can be identified both in mice bearing an OFA/iLR+ tumor (12, 17) and in patients with advanced breast carcinomas (17, 18). In a small series of CLL patients with early (Binet A, n = 4) and progressive disease (Binet C, n = 5), no relevant IL-10-secreting T cells specific for the iLR1 or iLR2 peptide were detectable (data not shown). However, as another important result of our study, we were able to detect significant frequencies of OFA-iLR-specific IFN--secreting CTLs in the PBMCs of early-stage patients with CLL and MM when compared with patients with progressive disease (see Table I). We hypothesize that OFA-iLR-specific CTLs can play a role in controlling OFA-iLR+ tumor cells in the early phase of disease but were deleted in an advanced stage, possibly as a result of a tumor escape mechanism. We are currently involved with experiments to elucidate more precisely a possible relationship between the occurrence of anti-OFA/iLRP-specific immune responses (humoral and T cell-mediated) and the stage of disease in patients with CLL and MM.
Taken together, we identified for the first time two distinct HLA-A*0201-specific peptide epitopes derived from the OFA-iLR protein. These peptides represent useful tools for both conducting tumor immunological studies and vaccination strategies in OFA/iLRP-expressing malignancies.
|
Disclosures |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Footnotes |
|---|
1 Address correspondence and reprint requests to Dr. Matthias Zeis, Department of Hematology, General Hospital St. Georg, Lohmühlenstrasse 5, D-20099 Hamburg, Germany. E-mail address: mzeis47{at}hotmail.com 
2 Abbreviations used in this paper: OFA/ILRP, oncofetal Ag-immature laminin receptor; DC, dendritic cell; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; BM, bone marrow; MM, multiple myeloma; iDC, immature DC; DOTAP, dioleoyloxy-trimethylammonium-propane-methylsulfate; GVHD, graft-vs-host disease.
Received for publication August 11, 2005. Accepted for publication February 27, 2006.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  B. Bruno, M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, R. Sorasio, A. Rambaldi, M. Casini, M. Parma, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo Blood, April 2, 2009; 113(14): 3375 - 3382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Almanzar, P. B. Olkhanud, M. Bodogai, C. Dell'Agnola, D. Baatar, S. M. Hewitt, C. Ghimenton, M. K. Tummala, A. T. Weeraratna, K. S. Hoek, et al. Sperm-Derived SPANX-B Is a Clinically Relevant Tumor Antigen That Is Expressed in Human Tumors and Readily Recognized by Human CD4+ and CD8+ T Cells Clin. Cancer Res., March 15, 2009; 15(6): 1954 - 1963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Qiu, G. Choi, L. Li, H. Wang, S. J. Pitteri, S. R. Pereira-Faca, A. L. Krasnoselsky, T. W. Randolph, G. S. Omenn, C. Edelstein, et al. Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera J. Clin. Oncol., November 1, 2008; 26(31): 5060 - 5066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biragyn, R. Schiavo, P. Olkhanud, K. Sumitomo, A. King, M. McCain, F. E. Indig, G. Almanzar, and D. Baatar Tumor-Associated Embryonic Antigen-Expressing Vaccines that Target CCR6 Elicit Potent CD8+ T Cell-Mediated Protective and Therapeutic Antitumor Immunity J. Immunol., July 15, 2007; 179(2): 1381 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Purbhoo, Y. Li, D. H. Sutton, J. E. Brewer, E. Gostick, G. Bossi, B. Laugel, R. Moysey, E. Baston, N. Liddy, et al. The HLA A*0201-restricted hTERT540-548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor Mol. Cancer Ther., July 1, 2007; 6(7): 2081 - 2091. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
